Strongbridge Biopharma plc to Host First Quarter 2021 Financial Results Conference Call on May 12, 2021
06 Mayo 2021 - 6:30AM
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that it will host a
conference call with members of Strongbridge’s management team
on May 12, 2021 at 8:30 a.m. ET to discuss the
Company’s first quarter 2021 financial results and corporate
highlights. The conference call will follow the anticipated release
of the Company’s financial results earlier that day.
Event DetailsStrongbridge will
host a conference call on Wednesday, May 12, 2021 at 8:30 a.m. ET.
To access the live call, dial (844) 285-7153 (domestic) or (478)
219-0180 (international) with conference ID 9478726. The conference
call will also be webcast from the Company’s website
at www.strongbridgebio.com under the “Investor/Webcasts and
Presentations” section. A replay of the call will be made available
for one week following the conference call. To hear a replay of the
call, dial (855) 859-2056 (domestic) or (404) 537-3406
(international) with conference ID 9478726.
About Strongbridge
BiopharmaStrongbridge Biopharma is a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs. Strongbridge’s rare endocrine
franchise includes RECORLEV® (levoketoconazole), a cortisol
synthesis inhibitor currently being studied in Phase 3
clinical studies for the treatment of endogenous Cushing’s
syndrome, and veldoreotide extended release, a pre-clinical
next-generation somatostatin analog being investigated for the
treatment of acromegaly and potential additional applications in
other conditions amenable to somatostatin receptor
activation. Both RECORLEV and veldoreotide have received
orphan drug designation from the FDA and the European Medicines
Agency. The Company’s rare neuromuscular franchise includes
KEVEYIS® (dichlorphenamide), the first and only FDA-approved
treatment for hyperkalemic, hypokalemic, and related variants of
primary periodic paralysis. KEVEYIS has orphan drug exclusivity in
the United States.
Contacts:
Corporate & Media RelationsElixir Health
Public RelationsLindsay Rocco+1
862-596-1304lrocco@elixirhealthpr.com
Investor RelationsSolebury TroutMike Biega+1
617-221-9660mbiega@soleburytrout.com
Strongbridge Biopharma (NASDAQ:SBBP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Strongbridge Biopharma PLC (NASDAQ): 0 recent articles
Más de Artículos de Noticias